Found: 3
Select item for more details and to access through your institution.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
- Published in:
- Oncogene, 2008, v. 27, n. 34, p. 4702, doi. 10.1038/onc.2008.109
- By:
- Publication type:
- Article
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 1, p. 94, doi. 10.1111/j.1463-1326.2011.01518.x
- By:
- Publication type:
- Article
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 1, p. 83, doi. 10.1111/j.1463-1326.2011.01517.x
- By:
- Publication type:
- Article